Jia‐Ren Lin

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Supplementary Figure S3 from Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS<i>-</i>Mutant Colorectal Cancers

  2026-06-17

• Supplementary Figure S2 from Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS<i>-</i>Mutant Colorectal Cancers

  2026-06-17

• Supplementary Figure S6 from Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS<i>-</i>Mutant Colorectal Cancers

  2026-06-17

• Supplementary Figure S5 from Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS<i>-</i>Mutant Colorectal Cancers

  2026-06-17

• Supplementary Figure S7 from Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS<i>-</i>Mutant Colorectal Cancers

  2026-06-17

• Supplementary Figure S4 from Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS<i>-</i>Mutant Colorectal Cancers

  2026-06-17

• Supplementary Figure S1 from Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS<i>-</i>Mutant Colorectal Cancers

  2026-06-17

• Spatial integration of protein and chromosomal states reveals early copy number changes and genotype-associated immune neighborhoods in serous ovarian cancer evolution

  Cancer Discovery · 2026-04-18

• Abstract LB124: Patient-derived organoid-immune cell co-cultures and spatial biology support a CD44v9 cancer stem cell-directed therapeutic strategy for adamantinomatous craniopharyngioma

  Cancer Research · 2026-04-17

• Immune profiling in a living human recipient of a gene-edited pig kidney

  Nature Medicine · 2026-01-01 · 12 citations

• MHC-II antigen presentation on cancer cells improves CD4+ T cell immunity and vaccine efficacyPreprint

  Research Square · 2025-12-18

• Supplementary Table S1 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

  2025-11-24

• Supplementary Fig. S7 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

  2025-11-24

• Supplementary Tables S2-13 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

  2025-11-24

• Supplementary Fig. S6 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

  2025-11-24

• Supplementary Fig. S4 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

  2025-11-24

• Supplementary Fig. S2 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

  2025-11-24

• Supplementary Fig. S3 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

  2025-11-24

• Supplementary Fig. S1 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

  2025-11-24

• Supplementary Fig. S5 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

  2025-11-24